Cellular Therapies for Mantle Cell Lymphoma

Transplant Cell Ther. 2021 May;27(5):363-370. doi: 10.1016/j.jtct.2021.01.026. Epub 2021 Feb 6.

Abstract

Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible for intensive therapies are offered an autologous hematopoietic cell transplant (HCT) as front-line consolidation followed by rituximab maintenance. Allogeneic HCT is an option for younger and fit patients with high-risk disease or in patients who have relapsed after autologous HCT. Recent advances in T cell engineering brought chimeric antigen receptor T cell (CAR T) therapy from the bench to the bedside, with brexucabtagene autoleucel being the first CAR T product approved by the US Food and Drug Administration for use in relapsed/refractory MCL. In this comprehensive review, we summarize the literature on available cellular therapies for MCL and present a treatment algorithm that incorporates HCT, autologous or allogeneic, and CAR T therapies.

Keywords: Allogeneic hematopoietic cell transplantation; Autologous hematopoietic cell transplantation; Chimeric antigen receptor; Mantle cell lymphoma; T cell therapy.

Publication types

  • Review

MeSH terms

  • Adult
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Mantle-Cell* / therapy
  • Neoplasm Recurrence, Local
  • Transplantation, Autologous
  • United States